Recent Posts
- And that’s a wrap 2023! Christmas with IR Department
- This is what the ASX and investors expect for gender diversity on your board
- 5 key lessons any company can take away from our foundational ESG report
- What small caps can take away from Amazon’s move to write emissions data into its supplier standards
- How Australian small caps are likely to be impacted by the new ISSB sustainability disclosure standards
Archives
Kazia Therapeutics CEO Dr James Garner talks with SmallCaps about what's on the horizon
Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical
Podcast - IR Department talks to Race Oncology's CSO Dr Daniel Tillett
Our Digital Content Producer, Paul Langley, talks with Race Oncology's CSO Dr Daniel Tillett, who explains how the recent clinical trials are evolving and what it means for the future. He gives a brief overview on the history of Race, their aspirations and milestones for development and eventual commercialisation of Zantrene.
HaemaLogiX's Tertia Dex explains the KappaMab antibody
Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene
Mosquito-borne diseases in Australia - an interview with Dr David Foster, CEO of Island Pharmaceuticals
Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham
Our Communications Director, Cherie Hartley, talks with AdAlta's CEO & M.D. Dr Tim Oldham at this year's Bioshares Biotech Summit, who takes us inside the mind of a biotech company. He discussed the importance of focus for a platform company, explains why making decisions on a day-to-day basis is so crucial for risk reduction and why they're investing in supporting core strategies as well as their target product profile.
IRD Invest March 2022 - Openpay
IRD Invest March 2022 - "Project: 2025"
Watch the replay of Openpay's CEO (Australia & New Zealand) Dion Appel.
IRD Invest March 2022 - Oventus
IRD Invest 31st March 2022 - "Project: 2025"
Watch the replay of Oventus CEO John Cox's presentation.
IRD Invest March 2022 - Pureprofile
IRD Invest 31st March 2022 - "Project: 2025"
Watch the replay of Pureprofile CEO Martin Filz's presentation.
Register now for our next IRD Invest virtual investor conference, where emerging tech companies will talk about the tailwinds driving their businesses
CEO in focus - Pureprofile's Martin Filz
UniSeed: UniSuper makes first venture capital foray with $75m funding (afr.com)
Servatus launches new trial into the effects of live biotherapeutics on insomnia
Servatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative.
Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer
Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)
Recent client coverage highlights
Project: 2025
Join us on Thurs 31 March for "IRD Invest - Project 2025"
As we look to accelerate the integration of advanced technology over the next three years, our fourth IRD Invest conference considers some of the benefits this change will bring, for businesses and society.
We are delighted to showcase a select number of emerging ASX listed tech companies on 31 March. The free virtual event will focus on companies that are paving the way forward with major advances in technology and innovation.
XPON’s CEO Matt Forman's presentation to the ASX Small – Mid Cap CEO conference
XPON’s CEO Matt Forman's presentation to the ASX Small – Mid Cap CEO conference
Interview with Ben Fogarty, CEO (UK) XPON
We speak to Ben Fogarty, CEO (UK & Europe) from XPON Technologies Group (see video below) about what the future holds for them and the impact of the upcoming ‘Metaverse’.